ArticleBlood cancer journal2024
A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements.
Abstract readLetter
In one paragraph
Article in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE study.Annals of hematology · 2025Trial
- Long-term treatment-free remission in CML after early dasatinib discontinuation due to interstitial pneumonitis.International journal of hematology · 2026Article
- Treatment-free remission in chronic myeloid leukaemia patients with accelerated phase or tyrosine kinase inhibitor therapy failure.British journal of haematology · 2025Article
- Treatment-Free Remission in Chronic Myeloid Leukemia: Revisiting the "W" Questions.European journal of haematology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Massimiliano BonifacioDepartment of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona and Azienda Ospedaliera Universitaria Integrata, Verona, Italy. massimiliano.bonifacio@univr.it.ORCID 0000-0003-0716-1686
Luigi ScaffidiDepartment of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona and Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Maria Cristina MiggianoDepartment of Hematology, San Bortolo Hospital, Vicenza, Italy.ORCID 0000-0003-1288-6104
Davide FacchinelliDepartment of Hematology, San Bortolo Hospital, Vicenza, Italy.
Luca TosoniDivision of Hematology and BMT, Azienda Sanitaria Universitaria Friuli Centrale and Department of Medical Area, University of Udine, Udine, Italy.
Sara PezoneDepartment of Medicine, Hematology and Clinical Immunology, University of Padua, Padova, Italy.
Davide GriguoloHematology Unit, Azienda Sanitaria Universitaria Giuliano-Isontina, Trieste, Italy.
Giulia CiottiOnco Hematology, Department of Oncology, Veneto Institute of Oncology, IOV-IRCCS, Padova, Italy.
Marco DaniniHematology Unit, Ca' Foncello Hospital, Treviso, Italy.
Andrea BernardelliDepartment of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona and Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Rita BrescianiDepartment of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona and Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Monica CavraroDepartment of Medicine, Oncology Unit, San Donà di Piave (VE), Italy.ORCID 0009-0008-0464-0554
Lara CroseraDepartment of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona and Azienda Ospedaliera Universitaria Integrata, Verona, Italy.ORCID 0000-0001-6756-8280
Elena De MarchHematology Unit, San Martino Hospital, Belluno, Italy.
Michele Dell'EvaHematology and Bone Marrow Transplant Unit, Ospedale Regionale San Maurizio, Bolzano, Italy.
Laura DoroteaOncology Unit, Ospedali Riuniti Padova Sud-Schiavonia, Monselice (PD), Italy.
Luca FrisonHematology Unit, Ospedale Dell'Angelo, Mestre-Venezia, Italy.
Lara FurlaniOncology Unit, Ospedale Mater Salutis, Legnago (VR), Italy.
Ilaria GianeselloDepartment of Medicine, Hematology and Clinical Immunology, University of Padua, Padova, Italy.
Ester LovatoDepartment of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona and Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Elena MarchettiDepartment of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona and Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Gianluca MorelliDivision of Hematology and BMT, Azienda Sanitaria Universitaria Friuli Centrale and Department of Medical Area, University of Udine, Udine, Italy.
Rikard MullaiDivision of Hematology and BMT, Azienda Sanitaria Universitaria Friuli Centrale and Department of Medical Area, University of Udine, Udine, Italy.
Umberto PizzanoDivision of Hematology and BMT, Azienda Sanitaria Universitaria Friuli Centrale and Department of Medical Area, University of Udine, Udine, Italy.
Simone ZolettoDepartment of Medicine, Hematology and Clinical Immunology, University of Padua, Padova, Italy.
Renato FaninDivision of Hematology and BMT, Azienda Sanitaria Universitaria Friuli Centrale and Department of Medical Area, University of Udine, Udine, Italy.
Mauro KramperaDepartment of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona and Azienda Ospedaliera Universitaria Integrata, Verona, Italy.ORCID 0000-0002-7280-2040
Livio TrentinDepartment of Medicine, Hematology and Clinical Immunology, University of Padua, Padova, Italy.ORCID 0000-0003-1222-6149
Elisabetta CalistriOnco Hematology, Department of Oncology, Veneto Institute of Oncology, IOV-IRCCS, Padova, Italy.
Giuseppe CarliDepartment of Hematology, San Bortolo Hospital, Vicenza, Italy.
Gianni BinottoDepartment of Medicine, Hematology and Clinical Immunology, University of Padua, Padova, Italy.
Mario TiribelliDivision of Hematology and BMT, Azienda Sanitaria Universitaria Friuli Centrale and Department of Medical Area, University of Udine, Udine, Italy.ORCID 0000-0001-9449-2621
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Leukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, MyeloidChronic DiseaseHumansProtein Kinase InhibitorsRemission InductionTreatment OutcomeProtein Kinase Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.